At a glance
ClinicalIndex Comparison RecordPhase 1Completed· 29 enrolled
Drug / intervention
group 1 +3 morebiological
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Immunotherapy of HLA-A2 Positive Stage III/IV Melanoma Patients With CpG7909, Tumor Antigenic Peptides and Montanide
In Brief
A Phase 1 clinical trial evaluating group 1, group 2, and 2 other interventions for Melanoma. Completed, enrolled 29 participants across 1 site.
Detailed Summary
The purpose of this study is to determine whether vaccination with tumor antigenic peptides and both CpG and Montanide adjuvants can induce an immune response in melanoma patients and to assess the safety of this vaccination.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsMelanoma
CountriesSwitzerland
CollaboratorsLudwig Institute for Cancer Research
Timeline
Phase 1CompletedFinished
2003200420052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
Enrollment StartApr 2003
First PostedJun 2005
Primary CompletionAug 2011
Study CompletionJun 2012
TodayJul 2026
First PostedJun 1, 2005
Enrollment StartApr 1, 2003
Primary CompletionAug 1, 2011
Study CompletionJun 1, 2012
TodayJul 2, 2026
Enrollment to primary: 8.3 yearsPosted 21.1 years ago
Interventions
group 1biological
Melan-A analog peptide + CpG + Montanide
group 2biological
Melan-A natural peptide + CpG + Montanide
group 3biological
Melan-A natural peptide + Tyrosinase YMD peptide + CpG + Montanide
group 4biological
Melan-A analog peptide + Tyrosinase YMD peptide + CpG + Montanide